Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Medisure Laboratories Pakistan Pvt Ltd

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000503 121 linked products · source seen 11 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx121product presentations
G55generic molecules
DF9dosage-form groups
TA10therapeutic areas
PKR121current price records
REG112registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage94%
priced packs safely normalized per unit
Comparable-market coverage93%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixMedisure Laboratories Pakistan Pvt LtdShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisure-laboratories-pakistan-pvt-ltdGenerated 11 Aug 2026Anti-infectives64 · 53%CNS & mental health23 · 19%Gastrointestinal & hepatology11 · 9%Cardiovascular8 · 7%Hematology & thrombosis7 · 6%Endocrine & metabolic2 · 2%Pain & musculoskeletal2 · 2%Other therapeutic areas4 · 3%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioMedisure Laboratories Pakistan Pvt LtdDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisure-laboratories-pakistan-pvt-ltdGenerated 11 Aug 2026121presentationsTablet62 · 51%Injection27 · 22%Capsule10 · 8%Cream6 · 5%Infusion5 · 4%Suspension5 · 4%Other forms6 · 5%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionMedisure Laboratories Pakistan Pvt LtdCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisure-laboratories-pakistan-pvt-ltdGenerated 11 Aug 2026112comparable productsBelow market median90 · 80%Near market median15 · 13%Above market median7 · 6%Company median price position-17.8%Lowest-price equivalents16Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsMedisure Laboratories Pakistan Pvt LtdCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/medisure-laboratories-pakistan-pvt-ltdGenerated 11 Aug 2026Nabiqasim Industries (Pvt) Ltd.,40 shared73% overlapMediate Pharmaceutical Pvt Ltd38 shared69% overlapNeutro Pharma (Pvt.) Ltd.,37 shared67% overlapEpharm Laboratories35 shared64% overlapPharmasol (Pvt) Ltd.34 shared62% overlapCCL Pharmaceuticals (Pvt.) Ltd.34 shared62% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives64 products · 53%
CNS & mental health23 products · 19%
Gastrointestinal & hepatology11 products · 9%
Cardiovascular8 products · 7%
Hematology & thrombosis7 products · 6%
Endocrine & metabolic2 products · 2%
Pain & musculoskeletal2 products · 2%
Oncology & immunology2 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins21 products · 17%
Antiepileptics13 products · 11%
Fluoroquinolone antibacterials9 products · 7%
Antipsychotics8 products · 7%
Macrolide antibacterials7 products · 6%
Antimalarials6 products · 5%
Antiemetics4 products · 3%
Antifungals4 products · 3%
Formulation footprint

Dosage forms

Tablet62 products
Injection27 products
Capsule10 products
Cream6 products
Infusion5 products
Suspension5 products
Solution3 products
Drops2 products
Syrup1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 CefsureCeftriaxone 10presentations 1 g, 2 g, 250 mg, 500 mg · Injection #2 TamlevLevetiracetam 7presentations 100 mg/mL, 250 mg, 500 mg/5 mL, 750 mg · Solution, Tablet, Injection #3 AmesureCiprofloxacin 6presentations 0.3 %, 200 mg/100 mL, 250 mg, 500 mg · Tablet, Infusion #4 ClarocinClarithromycin 4presentations 125 mg/5 mL, 250 mg, 500 mg · Drops, Tablet, Infusion #5 QuopineQuetiapine 4presentations 100 mg, 200 mg, 25 mg, 300 mg · Tablet #6 SuresefCefotaxime 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median9080% of comparable products
Near market median15within ±5% of median
Above market median76% of comparable products
Lowest-price equivalents16ties included
Company median price position -17.8% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Ylenol 500 mgParacetamol · Tablet · 10 x 10's PKR 0.80/tablet-77.5% vs market median Penicillamine D-Penicillamine … 250 mgPenicillamine · Tablet · 10's PKR 23.22/tablet-64.2% vs market median Biofloxacin 400 mgMoxifloxacin · Tablet · 1 x 5's PKR 77.41/tablet-57.1% vs market median Tamlev 750 mgLevetiracetam · Tablet · 30's PKR 67.12/tablet-48.8% vs market median Lactusure 3.35 gLactulose · Syrup · 120ml PKR 1.41/mL-40.2% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 40shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 38shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 37shared generics Epharm Laboratories144 products · 67 generics 35shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 34shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 34shared generics
Regulatory & price activity

Observed database signals

Registration numbers112
Price-history records130
Products with price history7
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date21 Oct 2025
Latest source observation11 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

121 results
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Vanmycin Vancomycin 1 g Injection 1's 098748 PKR 1,798.39 PKR 1,798.39/vial/unit 8% below median
Vanmycin Vancomycin 500 mg Injection 1's 098747 PKR 1,114.05 PKR 1,114.05/vial/unit 10% below median
Vorizole Voriconazole 200 mg Tablet 10's 084646 PKR 1,702.90 PKR 170.29/tablet 16% below median
Xartoban Rivaroxaban 20 mg Tablet 7's 104352 PKR 6,266.60 PKR 895.23/tablet Near median
Xartoban Rivaroxaban 20 mg Tablet 14's 104352 PKR 11,907.93 PKR 850.57/tablet Near median
Xartoban Rivaroxaban 20 mg Tablet 10's 104352 PKR 8,505.66 PKR 850.57/tablet Near median
Xendone Risperidone 4 mg Tablet 10's 044214 PKR 603.76 PKR 60.38/tablet 16% below median
Xendone Risperidone 3 mg Tablet 10's 044213 PKR 464.43 PKR 46.44/tablet 20% below median
Xendone Risperidone 2 mg Tablet 10's 044212 PKR 301.88 PKR 30.19/tablet 16% below median
Xendone Risperidone 1 mg Tablet 10's 044211 PKR 185.77 PKR 18.58/tablet 18% below median
Xopac Plus Omeprazole 40 mg Capsule 14's 055600 PKR 387.03 PKR 27.65/capsule 19% below median
Xopra Omeprazole 20 mg Capsule 14's 029241 PKR 464.43 PKR 33.17/capsule 70% above median
Xopra Omeprazole 40 mg Infusion 1's 074958 PKR 464.43 PKR 464.43/vial/unit No comparator
Xopra Omeprazole 20 mg Capsule 7 × 14's 029241 PKR 2,167.33 PKR 22.12/capsule 13% above median
Ylenol Paracetamol 500 mg Tablet 10 x 10's 032812 PKR 79.58 PKR 0.80/tablet 77% below median
Zosure-10 Simvastatin 10 mg Tablet 10's 029243 PKR 263.18 PKR 26.32/tablet 9% below median
Zosure-20 Simvastatin 20 mg Tablet 10's 029252 PKR 448.95 PKR 44.90/tablet Near median
Zyxov Linezolid 100 mg/5 mL Suspension 120ml 091071 PKR 1,029.48 PKR 8.58/mL 22% below median
Zyxov Linezolid 200 mg/100 mL IV infusion 1*100ml 075903 PKR 535.64 — No comparator
Zyxov Linezolid 600 mg Tablet 12's 042428 PKR 3,096.19 PKR 258.02/tablet 34% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.